Evidence map›Paper›PMID 25132681›Full record

ArticleCancer medicine2014

Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers.

Margaret E Wright, Demetrius Albanes, Ann B Moser, Stephanie J Weinstein, Kirk Snyder, Satu Männistö, Peter H Gann

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Phytol and its metabolites phytanic and pristanic acids for risk of cancer: current evidence and future directions.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2020
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Margaret E WrightDepartment of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois; American Academy of Pediatrics, Elk Grove Village, Illinois.
Demetrius Albanes
Ann B Moser
Stephanie J Weinstein
Kirk Snyder
Satu Männistö
Peter H Gann
American Academy of Pediatrics · USAssociated Management Services (United States) · USDepartment of Health and Human Services · USFinnish Institute for Health and Welfare · FIKennedy Krieger Institute · USUnited States Department of Health and Human Services · USUniversity of Illinois Chicago · US

Funding

U S-FINLAND STUDIES OF NUTRITION AND CANCERN01CN045165 · CN · NATIONAL PUBLIC HEALTH INSTITUTE · PI HEINONEN, OLLI P · 1985 to 1996
–
CCR NIH HHS N01-RC-37004CCR NIH HHS N01-RC-45035NCI NIH HHS N01-CN-45165PHS HHS HHSN261201000006C
6 · The paper itself

Abstract

Phytanic acid is a saturated branched-chain fatty acid found predominantly in red meat and dairy products, and may contribute to the elevated risks of prostate cancer associated with higher consumption of these foods. Pristanic acid is formed during peroxisomal oxidation of phytanic acid, and is the direct substrate of α-Methyl-CoA-Racemase (AMACR)--an enzyme that is consistently overexpressed in prostate tumors relative to benign tissue. We measured phytanic and pristanic acids as percentages of total fatty acids by gas chromatography-mass spectrometry in prediagnostic blood samples from 300 prostate cancer cases and 300 matched controls, all of whom were participants in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study supplementation trial and follow-up cohort. In addition to providing a fasting blood sample at baseline, all men completed extensive diet, lifestyle, and medical history questionnaires. Among controls, the strongest dietary correlates of serum phytanic and pristanic acids were saturated fat, dairy fat, and butter (r = 0.50 and 0.40, 0.46 and 0.38, and 0.40 and 0.37, respectively; all P-values <0.001). There was no association between serum phytanic acid and risk of total or aggressive prostate cancer in multivariate logistic regression models (for increasing quartiles, odds ratios (OR) and 95% confidence intervals (CI) for aggressive cancer were 1.0 (referent), 1.62 (0.97-2.68), 1.12 (0.66-1.90), and 1.14 (0.67-1.94), P(trend) = 0.87). Pristanic acid was strongly correlated with phytanic acid levels (r = 0.73, P < 0.0001), and was similarly unrelated to prostate cancer risk. Significant interactions between phytanic and pristanic acids and baseline circulating β-carotene concentrations were noted in relation to total and aggressive disease among participants who did not receive β-carotene supplements as part of the original ATBC intervention trial. In summary, we observed no overall association between serum phytanic and pristanic acid levels and prostate cancer risk. Findings indicating that the direction and magnitude of these associations depended upon serum levels of the antioxidant β-carotene among men not taking β-carotene supplements should be interpreted cautiously, as they are likely due to chance.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesFatty AcidsGas Chromatography-Mass SpectrometryHumansMaleMiddle AgedPhytanic AcidProstatic NeoplasmsRandomized Controlled Trials as TopicRisk FactorsSmokingBiomarkers, TumorFatty AcidsPhytanic Acidpristanic acidBiomarkerdietphytanic acidpristanic acidprostate cancer

Identifiers

PMID25132681
PMCPMC4298383
OpenAlexW1991836865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.